citric acid, anhydrous has been researched along with Hemorrhage in 63 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
Hemorrhage: Bleeding or escape of blood from a vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In high risk critically ill patients citrate based anticoagulation for CVVH is safe in terms of bleeding complications and transfusion requirements." | 2.72 | Safety of citrate based hemofiltration in critically ill patients at high risk for bleeding: a comparison with nadroparin. ( Boerma, EC; Kingma, WP; Postma, SR; Van der Voort, PH; Van Roon, EN, 2006) |
| " The interruption may impair the solute clearance as it causes under dosing of CRRT." | 2.66 | Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. ( Akazawa, M; Fujii, T; Kataoka, Y; Nakata, Y; Takahashi, S; Tsujimoto, H; Tsujimoto, Y, 2020) |
| "Regional citrate anticoagulation seems to be a safe anticoagulation method in liver failure patients underwent CRRT and could yield a favorable filter lifespan." | 2.61 | Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. ( Bai, M; Chen, X; Li, L; Sun, S; Yu, Y; Zhang, W; Zhao, L, 2019) |
| "During critical illness, regional anticoagulation with citrate for CRRT seems superior to heparin anticoagulation concerning tolerance and safety, mainly due to less bleeding." | 2.46 | Citrate anticoagulation for continuous renal replacement therapy in the critically ill. ( Oudemans-van Straaten, HM, 2010) |
| " Relevant toxic effects (midzonal hepatocellular necrosis, gall bladder hemorrhage) were found in mice treated with 10 nm AgNPs, while in mice treated with 40 nm and 100 nm AgNPs lesions were milder or negligible, respectively." | 1.43 | Tissue distribution and acute toxicity of silver after single intravenous administration in mice: nano-specific and size-dependent effects. ( Argentiere, S; Aureli, F; Bianchessi, S; Cella, C; Cubadda, F; D'Amato, M; De Maglie, M; Lenardi, C; Mattiello, S; Milani, P; Raggi, A; Recordati, C; Scanziani, E, 2016) |
| " No adverse effects of RCA were observed." | 1.36 | Regional citrate anticoagulation is safe in intermittent high-flux haemodialysis treatment of children and adolescents with an increased risk of bleeding. ( Bonzel, KE; Büscher, R; Ehrich, JH; Kreuzer, M; Offner, G; Pape, L, 2010) |
| " Citrate anticoagulation during single-needle hemodialysis, according to our protocol, is safe and effective." | 1.33 | Citrate anticoagulation for single-needle hemodialysis: safety and efficacy. ( Buturović-Ponikvar, J; Gubensek, J; Ponikvar, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (19.05) | 18.7374 |
| 1990's | 4 (6.35) | 18.2507 |
| 2000's | 7 (11.11) | 29.6817 |
| 2010's | 31 (49.21) | 24.3611 |
| 2020's | 9 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Miyaji, MJ | 1 |
| Ide, K | 1 |
| Takashima, K | 1 |
| Maeno, M | 1 |
| Krallman, KA | 1 |
| Lazear, D | 1 |
| Goldstein, SL | 2 |
| Xu, YW | 1 |
| Huang, NY | 1 |
| Li, S | 3 |
| Chen, W | 2 |
| Jiao, J | 4 |
| Yu, Y | 6 |
| Wei, S | 1 |
| Tian, X | 2 |
| Yang, X | 2 |
| Feng, S | 1 |
| Li, Y | 7 |
| Sun, S | 4 |
| Zhang, P | 1 |
| Bai, M | 4 |
| Zhao, L | 4 |
| Ma, F | 2 |
| Wang, Y | 9 |
| He, L | 1 |
| Zhou, M | 2 |
| Jing, R | 1 |
| Li, L | 9 |
| Huang, C | 1 |
| Lin, T | 1 |
| Song, L | 1 |
| Huang, R | 1 |
| Huang, Y | 3 |
| Tang, S | 1 |
| Lin, Q | 1 |
| Zhang, Y | 7 |
| Wu, X | 3 |
| Liang, H | 3 |
| Wu, Y | 3 |
| Chen, Y | 1 |
| Ma, J | 1 |
| Feng, Z | 1 |
| Li, Z | 3 |
| Xu, L | 2 |
| Fu, X | 1 |
| Ye, Z | 1 |
| Liu, S | 2 |
| Liang, X | 2 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 1 |
| Zhao, Y | 3 |
| Wang, J | 6 |
| Huang, L | 2 |
| Hu, K | 1 |
| Liu, H | 4 |
| Wang, H | 3 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 4 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 1 |
| Cheng, T | 1 |
| Zhou, X | 1 |
| Wang, B | 4 |
| Zhang, Q | 5 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Gai, QY | 3 |
| Wang, W | 2 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Wang, X | 4 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Liu, J | 4 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 2 |
| Jiang, H | 1 |
| He, C | 2 |
| Xiao, Z | 1 |
| Xu, J | 2 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 1 |
| Li, X | 4 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 4 |
| Liu, Z | 4 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Zhang, X | 6 |
| Xu, N | 1 |
| Wang, R | 1 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 3 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Han, J | 2 |
| Zhang, C | 3 |
| Chen, L | 2 |
| Li, W | 3 |
| Wang, T | 3 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 2 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 2 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 1 |
| Yan, R | 1 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Zhu, X | 1 |
| Huang, X | 2 |
| Xu, H | 2 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 2 |
| Li, J | 7 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Liu, Y | 7 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 2 |
| Zhang, H | 1 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 2 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 3 |
| Hu, T | 1 |
| Wang, F | 2 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 3 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 2 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 2 |
| Tang, J | 3 |
| Chen, Z | 3 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Zhang, Z | 2 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 3 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 2 |
| Jiang, X | 2 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 1 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 2 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 1 |
| Liu, C | 2 |
| Liu, W | 1 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 1 |
| Hu, B | 1 |
| Fu, P | 2 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 1 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 4 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 2 |
| Shao, B | 1 |
| Ma, X | 1 |
| Bi, Z | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 1 |
| Zhang, L | 4 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Li, C | 2 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 2 |
| Liu, X | 3 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 2 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Yao, C | 1 |
| Zhang, B | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 2 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 2 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 2 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 1 |
| Shen, Y | 1 |
| Wang, Q | 2 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Xu, X | 1 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Gu, C | 1 |
| Huang, J | 2 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 3 |
| Xue, H | 1 |
| Zhang, W | 3 |
| Ruan, Z | 1 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Wang, Z | 3 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 1 |
| Luo, M | 1 |
| Wu, J | 1 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Chen, J | 2 |
| Bi, X | 2 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 1 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 1 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 1 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Sun, X | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Zhuang, F | 1 |
| Ding, F | 1 |
| Zarbock, A | 2 |
| Küllmar, M | 2 |
| Kindgen-Milles, D | 4 |
| Wempe, C | 2 |
| Gerss, J | 2 |
| Brandenburger, T | 2 |
| Dimski, T | 2 |
| Tyczynski, B | 1 |
| Jahn, M | 1 |
| Mülling, N | 1 |
| Mehrländer, M | 1 |
| Rosenberger, P | 1 |
| Marx, G | 2 |
| Simon, TP | 1 |
| Jaschinski, U | 1 |
| Deetjen, P | 1 |
| Putensen, C | 1 |
| Schewe, JC | 1 |
| Kluge, S | 2 |
| Jarczak, D | 1 |
| Slowinski, T | 4 |
| Bodenstein, M | 1 |
| Meybohm, P | 1 |
| Wirtz, S | 1 |
| Moerer, O | 1 |
| Kortgen, A | 1 |
| Simon, P | 1 |
| Bagshaw, SM | 1 |
| Kellum, JA | 1 |
| Meersch, M | 2 |
| Tsujimoto, H | 1 |
| Tsujimoto, Y | 1 |
| Nakata, Y | 1 |
| Fujii, T | 1 |
| Takahashi, S | 1 |
| Akazawa, M | 1 |
| Kataoka, Y | 1 |
| Goet, E | 1 |
| Wentz, B | 1 |
| Frank, RD | 1 |
| Meijers, B | 1 |
| Metalidis, C | 1 |
| Vanhove, T | 1 |
| Poesen, R | 1 |
| Kuypers, D | 2 |
| Evenepoel, P | 2 |
| Huguet, M | 1 |
| Rodas, L | 1 |
| Blasco, M | 1 |
| Quintana, LF | 1 |
| Mercadal, J | 1 |
| Ortiz-Pérez, JT | 1 |
| Rovira, I | 1 |
| Poch, E | 1 |
| Zhu, W | 1 |
| Peck, Y | 1 |
| Iqbal, J | 1 |
| Wang, DA | 1 |
| Tuerdi, B | 1 |
| Zuo, L | 1 |
| Sun, H | 1 |
| Li, G | 1 |
| Skagerlind, MSE | 1 |
| Stegmayr, BG | 2 |
| Coleman, JR | 1 |
| Moore, EE | 1 |
| Chapman, MP | 1 |
| Banerjee, A | 1 |
| Silliman, CC | 1 |
| Ghasabyan, A | 1 |
| Chandler, J | 1 |
| Samuels, JM | 1 |
| Sauaia, A | 1 |
| Ricci, D | 1 |
| Panicali, L | 1 |
| Cavallari, G | 1 |
| Facchini, MG | 1 |
| Mancini, E | 1 |
| Gao, J | 1 |
| Jin, D | 1 |
| Tang, L | 1 |
| Pan, K | 1 |
| Kalb, R | 1 |
| Kram, R | 1 |
| Morgera, S | 1 |
| Morabito, S | 2 |
| Pistolesi, V | 2 |
| Tritapepe, L | 2 |
| Vitaliano, E | 1 |
| Zeppilli, L | 2 |
| Polistena, F | 2 |
| Fiaccadori, E | 1 |
| Pierucci, A | 2 |
| Atalan, HK | 1 |
| Gucyetmez, B | 1 |
| Dumantepe, M | 1 |
| Berktas, M | 1 |
| Denizalti, TB | 1 |
| Tarhan, İA | 1 |
| Ozler, A | 1 |
| Gutierrez-Bernays, D | 1 |
| Ostwald, M | 1 |
| Anstey, C | 1 |
| Campbell, V | 1 |
| Recordati, C | 1 |
| De Maglie, M | 1 |
| Bianchessi, S | 1 |
| Argentiere, S | 1 |
| Cella, C | 1 |
| Mattiello, S | 1 |
| Cubadda, F | 1 |
| Aureli, F | 1 |
| D'Amato, M | 1 |
| Raggi, A | 1 |
| Lenardi, C | 1 |
| Milani, P | 1 |
| Scanziani, E | 1 |
| Marn Pernat, A | 1 |
| Medved, B | 1 |
| Gubenšek, J | 2 |
| Premru, V | 1 |
| Knap, B | 1 |
| Buturovic-Ponikvar, J | 2 |
| Ponikvar, R | 2 |
| Trumper, C | 1 |
| Yeoh, CJ | 1 |
| Ng, SY | 1 |
| Goh, BK | 1 |
| Rico, MP | 1 |
| Fernández Sarmiento, J | 1 |
| Rojas Velasquez, AM | 1 |
| González Chaparro, LS | 1 |
| Gastelbondo Amaya, R | 1 |
| Mulett Hoyos, H | 1 |
| Tibaduiza, D | 1 |
| Quintero Gómez, AM | 1 |
| Ou, H | 1 |
| Peng, Y | 1 |
| Kissling, S | 1 |
| Legallais, C | 1 |
| Pruijm, M | 1 |
| Teta, D | 1 |
| Vogt, B | 1 |
| Rondeau, E | 1 |
| Ridel, C | 1 |
| Nseir, V | 1 |
| Rachas, A | 1 |
| Elias, M | 1 |
| Francois, H | 1 |
| Nnang Obada, E | 1 |
| Lorenzo, HK | 1 |
| Charpentier, B | 1 |
| Durrbach, A | 1 |
| Beaudreuil, S | 1 |
| Oudemans-van Straaten, HM | 2 |
| Bosman, RJ | 1 |
| Koopmans, M | 1 |
| van der Voort, PH | 2 |
| Wester, JP | 1 |
| van der Spoel, JI | 1 |
| Dijksman, LM | 1 |
| Zandstra, DF | 1 |
| Kreuzer, M | 1 |
| Bonzel, KE | 1 |
| Büscher, R | 1 |
| Offner, G | 1 |
| Ehrich, JH | 1 |
| Pape, L | 1 |
| Arepally, GM | 1 |
| Strampelli, E | 1 |
| Jonsson, P | 1 |
| Mahmood, D | 1 |
| HARRIS, J | 2 |
| KIESEWETTER, WB | 2 |
| DIXON, WG | 1 |
| ERMAKOVA, NM | 1 |
| ZOLOTOKRYLINA, ES | 1 |
| NOSOVA, EA | 1 |
| NIEPOTH, G | 1 |
| NIKOLAI, N | 1 |
| Mariano, F | 1 |
| Tetta, C | 1 |
| Stella, M | 1 |
| Biolino, P | 1 |
| Miletto, A | 1 |
| Triolo, G | 1 |
| Brophy, PD | 1 |
| Somers, MJ | 1 |
| Baum, MA | 1 |
| Symons, JM | 1 |
| McAfee, N | 1 |
| Fortenberry, JD | 1 |
| Rogers, K | 1 |
| Barnett, J | 1 |
| Blowey, D | 1 |
| Baker, C | 1 |
| Bunchman, TE | 1 |
| Balik, M | 1 |
| Waldauf, P | 1 |
| Plásil, P | 1 |
| Pachl, J | 1 |
| Postma, SR | 1 |
| Kingma, WP | 1 |
| Boerma, EC | 1 |
| Van Roon, EN | 1 |
| Dejagere, T | 1 |
| Verhamme, P | 1 |
| Claes, K | 1 |
| Bammens, B | 1 |
| Vanrenterghem, Y | 1 |
| Yuasa, S | 1 |
| Pinnick, RV | 1 |
| Wiegmann, TB | 1 |
| Diederich, DA | 1 |
| Collart, F | 1 |
| Wens, R | 1 |
| Dratwa, M | 1 |
| Palsson, R | 1 |
| Niles, JL | 1 |
| Mehta, RL | 1 |
| McDonald, BR | 1 |
| Ward, DM | 1 |
| Ahmad, S | 1 |
| Yeo, KT | 1 |
| Jensen, WM | 1 |
| Landicho, D | 1 |
| Gregory, B | 1 |
| Moritz, JL | 1 |
| Kenny, M | 1 |
| Perdrix, JP | 1 |
| Lepape, A | 1 |
| Gronlier, T | 1 |
| Grozel, JM | 1 |
| Banssillon, V | 1 |
| Flanigan, MJ | 2 |
| Von Brecht, J | 1 |
| Freeman, RM | 2 |
| Lim, VS | 2 |
| von Brecht, JH | 1 |
| Holm, HA | 1 |
| Abildgaard, U | 1 |
| Kalvenes, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Filters Useful Life, Metabolic Control, Electrolyte Profile and Acid-base Balance During Regional Anticoagulation With 4% Trisodium Citrate in Patients Undergoing CVVHDF: Effects of Increased Blood Flow[NCT05796661] | 27 participants (Anticipated) | Interventional | 2023-01-09 | Recruiting | |||
| Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy During Veno-venous ECMO: a Crossover Randomized Controlled Study[NCT05148026] | 20 participants (Anticipated) | Interventional | 2021-11-14 | Recruiting | |||
| Regional Citrate Versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury[NCT02669589] | Phase 4 | 638 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Regional Citrate Versus Systemic Heparin Anticoagulation for Super High-flux Continuous Hemodialysis in Septic Shock: Effect on Middle Molecular Weight Molecules Clearances[NCT01839578] | 30 participants (Anticipated) | Interventional | 2013-05-31 | Recruiting | |||
| Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU = Multicentre, Controlled, Randomised Superiority Trial[NCT01962116] | Phase 3 | 405 participants (Actual) | Interventional | 2013-06-14 | Completed | ||
| Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin[NCT00286273] | Phase 4 | 215 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Citrate Versus Heparin Anticoagulation in Continuous Venovenous Hemofiltration in Critically Ill Patients With Acute Renal Failure: A Randomized Clinical Trial[NCT00209378] | 139 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| A Comparison of Dilute Unfractionated Heparin and Standard Concentrated Unfractionated Heparin Protocols for Anticoagulation of the Extra-corporeal Circuit During Continuous Renal Replacement Therapy in the ICU[NCT01318811] | Phase 4 | 12 participants (Actual) | Interventional | 2011-03-31 | Terminated (stopped due to lack of recruitment) | ||
| Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial[NCT00798525] | Phase 4 | 70 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Supply of Lepirudin ended on 01. April 2012, thus trial terminated on 31. March 2012) | ||
| Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure: Effects on Platelet Responsiveness in the Systemic Circulation and Across the Filter.[NCT00890214] | Phase 4 | 23 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates[NCT00965328] | Phase 4 | 14 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)[NCT02860130] | Phase 3 | 34 participants (Actual) | Interventional | 2016-09-27 | Terminated (stopped due to Study halted due to low recruitment, unrelated to safety or efficacy reasons) | ||
| Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Renal Failure: a Randomized Controlled Trial[NCT01269112] | Phase 4 | 103 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.[NCT01228292] | Phase 4 | 250 participants (Anticipated) | Interventional | 2011-01-31 | Not yet recruiting | ||
| [NCT02478242] | Phase 4 | 60 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Magnesium Balance of Citrate-based Continuous Venovenous Hemofiltration, Effect of Citrate Dose.[NCT02194569] | 36 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| [NCT02423642] | 30 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Circuit Survival and Efficacy for Middle Molecular-weight Solute Elimination Between Nafamostat Infusion and Heparinized Saline Priming[NCT01486485] | Phase 3 | 160 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| [NCT01761994] | Phase 4 | 66 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Citrate Versus Heparin in Continuous Renal Replacement Therapy : Effect on Cardiovascular System and Clot Circuit in Critically Ill Patients[NCT04865510] | 41 participants (Actual) | Interventional | 2019-02-04 | Completed | |||
| Prismaflex Therapeutic Plasma Exchange: Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation[NCT04351438] | 108 participants (Actual) | Observational | 2012-01-31 | Active, not recruiting | |||
| Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED Focused on the Prevention of RRT-related Hypophosphatemia and Optimization of Acid-base Balance: a Pilot Study[NCT03976440] | 30 participants (Anticipated) | Observational | 2019-06-01 | Active, not recruiting | |||
| Evaluation of a Simplified Protocol for Regional Citrate Anticoagulation in Continuous Venovenous Hemodiafiltration[NCT00583765] | 20 participants (Actual) | Observational | 2005-04-30 | Completed | |||
| HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification[NCT03312036] | 12 participants (Actual) | Interventional | 2013-06-06 | Completed | |||
| Heparin-Coated Polyacrylonitrile Membrane Versus Regional Citrate Anticoagulation: a Prospective Randomised Study of 2 Anticoagulation Strategies in Patients at Risk of Bleeding[NCT00395824] | Phase 3 | 33 participants | Interventional | 2005-01-31 | Completed | ||
| Continuous Renal Replacement Therapy With Anticoagulation-free Regimen in Bleeding-risk Patients Using oXiris Membrane - CARROM Study[NCT01779635] | 20 participants (Actual) | Interventional | 2013-08-31 | Completed | |||
| Regional Citrate Anticoagulation in ECMO[NCT00968565] | Early Phase 1 | 2 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary endpoint for this study will be the difference in filter life in hours between the group receiving dilute heparin and the group receiving standard concentrated heparin. (NCT01318811)
Timeframe: 72 hours
| Intervention | hours (Mean) |
|---|---|
| Dilute Heparin | 22.46 |
| Standard Concentrated Heparin | 33 |
Information on major bleeding complications, and need for blood product transfusions will be collected. (NCT01318811)
Timeframe: 72 hours
| Intervention | clinical active major bleeding episodes (Number) |
|---|---|
| Dilute Heparin | 0 |
| Standard Concentrated Heparin | 0 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | beats/min (Mean) |
|---|---|
| Prismocitrate 18 | 2.1 |
| No Systemic Anticoagulation | 3.2 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | breaths/Min (Mean) |
|---|---|
| Prismocitrate 18 | -2.1 |
| No Systemic Anticoagulation | -1.1 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | degree celsius (Mean) |
|---|---|
| Prismocitrate 18 | 0.2 |
| No Systemic Anticoagulation | -0.1 |
(NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | Hours (Mean) |
|---|---|
| Prismocitrate 18 | 0 |
| No Systemic Anticoagulation | 14.4 |
Training conducted on administration of Prismocitrate 18 to demonstrate the understanding of the user groups on how to use the solution by passing an assessment at the end of training. The user groups who needed to be assessed prior to use of Prismocitrate 18 in the clinical trial setting were to be comprised of physicians, nurses, and other clinicians who were part of prescribing, initiating or modifying treatment during the 120 hour Treatment Period. The training assessment was housed on a restricted access study website. Study personnel who completed the training assessment have a completion date listed which indicates that the individual received a passing score of 80% or better on the training assessment. (NCT02860130)
Timeframe: Prior to study use of Prismocitrate 18
| Intervention | site facility staff (Number) |
|---|---|
| Prismocitrate 18 | 6 |
(NCT02860130)
Timeframe: Up to 30 days post study CRRT treatment completion
| Intervention | Events (Number) |
|---|---|
| Prismocitrate 18 | 0 |
| No Systemic Anticoagulation | 1 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 1.1 | 1.7 | 1.1 | 0.6 | 1.7 | 0.9 | 2.1 | 1.9 | 0.4 | 1.2 | 2.1 | -2.1 | 4 | 3.7 | 3.1 | 2.2 | -1.0 | 0.8 | -2.8 | -2.0 |
| Prismocitrate 18 | 0.4 | -1.3 | 0.3 | 2.4 | 1.3 | 3 | 2.8 | 2.4 | 1.3 | 3.7 | 3.2 | 3.6 | 2.5 | 4 | 3 | 3.5 | 1.6 | 3.5 | 2.7 | 2.8 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| No Systemic Anticoagulation | -6.4 | 2.8 |
| Prismocitrate 18 | 1.9 | -2.8 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Hour | 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | -0.0 | -0.0 | -0.0 | -0.0 | -0.1 | -0.0 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.2 | -0.1 | -0.2 | -0.1 | -0.1 | -0.2 | -0.1 |
| Prismocitrate 18 | -0.0 | 0.1 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.3 | 0.2 | 0.4 |
Systemic blood iCa concentrations (NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Hour | 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 hours | 60 hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 0 | 0 | 0 | 0 | -0.0 | 0 | -0.0 | 0 | 0 | -0.0 | -0.0 | -0.0 | 0 | 0 | -0.0 | -0.0 | -0.0 | 0 | 0 | 0 | -0.0 |
| Prismocitrate 18 | -0.1 | -0.1 | -0.0 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | -0.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0.1 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | pH (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 0.1 | 0.1 | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 0.1 | -0.0 | 0 |
| Prismocitrate 18 | -0.0 | -0.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | -0.0 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | -2.3 | -3.5 | -2.2 | -2.9 | -3.6 | -4 | -3.5 | -2.8 | -3.2 | -2.3 | -3.2 | 0 | -2.0 | -3.0 | -2.1 | -1.7 | -1.7 | 0.6 | 0.7 | -1.2 |
| Prismocitrate 18 | 0.6 | 0.6 | 0.2 | -0.5 | 1.6 | 0.5 | 0.7 | 0.7 | 0.3 | 0.4 | 1.1 | 1 | 0.7 | 0.8 | 0.8 | 1.6 | 1.5 | 0.8 | 1 | -0.3 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 2.4 | 2.9 | 2.3 | 2 | 2.9 | 2.6 | 3.6 | 2.4 | 2.1 | 2.4 | 2.6 | 0.1 | 2.9 | 2.5 | 2.2 | 1.4 | -1.1 | -0.4 | -2.8 | -1.5 |
| Prismocitrate 18 | 0.2 | 0.8 | 1.3 | 2.8 | 2.9 | 3.3 | 3.3 | 2.7 | 2.7 | 4.7 | 3.7 | 4.2 | 2.8 | 3.3 | 3.3 | 2.8 | 2.2 | 2.7 | 3.8 | 2.8 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 0.6 | 0.9 | 0.8 | 1.3 | 1.1 | 0.6 | 0.5 | 1.3 | 0.9 | 1 | 1 | 1.7 | 2.4 | 2.1 | 2.3 | 2.4 | 2.6 | 1.3 | 1.1 | 1 |
| Prismocitrate 18 | -1.9 | -3.4 | -3.9 | -3.9 | -5.5 | -5.0 | -4.9 | -5.1 | -5.4 | -5.9 | -5.3 | -5.6 | -5.5 | -5.8 | -5.9 | -6.2 | -6.0 | -5.9 | -7.7 | -8.1 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 0 | -0.0 | 0 | -0.0 | 0 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0.1 | 0.1 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 |
| Prismocitrate 18 | -0.1 | -0.1 | -0.1 | -0.2 | -0.1 | -0.1 | -0.2 | -0.2 | -0.2 | -0.1 | -0.1 | -0.1 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | -0.1 | -0.2 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | -0.4 | -0.4 | -0.4 | -0.4 | -0.5 | -0.4 | -0.5 | -0.4 | -0.4 | -0.4 | -0.4 | -0.2 | -0.4 | -0.4 | -0.3 | -0.5 | -0.4 | -0.4 | 0.2 | -0.2 |
| Prismocitrate 18 | -0.3 | -0.3 | -0.5 | -0.7 | -0.6 | -0.7 | -0.8 | -0.9 | -0.8 | -0.9 | -0.8 | -0.8 | -0.8 | -0.8 | -0.8 | -0.8 | -0.7 | -0.8 | -0.9 | -0.8 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | -0.1 | -0.1 | -0.1 | -0.2 | -0.1 | -0.0 | -0.0 | -0.0 | 0.1 | 0.1 | 0.3 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | 0 | 0.1 | 0.2 | 0.1 |
| Prismocitrate 18 | -0.4 | -0.4 | -0.7 | -0.9 | -0.9 | -1.0 | -1.0 | -1.0 | -1.2 | -1.2 | -1.2 | -1.2 | -1.2 | -1.3 | -1.4 | -1.1 | -1.2 | -1.2 | -1.5 | -1.1 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 0.4 | -0.1 | 0.5 | 0.4 | 0.4 | -0.3 | -0.4 | 1.2 | 0.5 | 1 | 0.3 | 2.5 | 2.6 | 1.7 | 2.2 | 2.3 | 1.1 | 0.7 | 1.4 | 1 |
| Prismocitrate 18 | -1.1 | -1.6 | -1.7 | -1.7 | -1.9 | -1.1 | -0.7 | -1.5 | -1.3 | -1.3 | -0.7 | -0.8 | -1.8 | -2.2 | -1.8 | -2.0 | -1.8 | -2.4 | -2.8 | -3.7 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | ratio (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Hour | 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 |
| Prismocitrate 18 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 |
Evaluates the efficacy of using Prismocitrate 18 in delivering the prescribed CRRT dose, with delivered dose based on (daily) average effluent rate divided by (daily) average weight and expressed as mL/kg/hour. (NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | mL/kg/hour (Mean) | ||||
|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | |
| No Systemic Anticoagulation | 30.34 | 32.49 | 32.29 | 35.19 | 33.31 |
| Prismocitrate 18 | 32.3 | 33.12 | 31.62 | 31.93 | 32.83 |
Post-filter blood iCa concentrations will only be measured in the Prismocitrate 18 arm. The extracorporeal circuit (post-filter). (NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Hour | 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 hours | 60 hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| Prismocitrate 18 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 |
(NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | Events (Number) | |||
|---|---|---|---|---|
| Gastrointestinal | M150 filter | ostomy and rectum | upper Gastrointestinal tract | |
| No Systemic Anticoagulation | 4 | 1 | 1 | 1 |
| Prismocitrate 18 | 1 | 0 | 0 | 0 |
(NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | participants (Number) | |
|---|---|---|
| 3 Transfusions | 27 Transfusions | |
| No Systemic Anticoagulation | 2 | 1 |
| Prismocitrate 18 | 1 | 0 |
(NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| 0 Bleeding Events | 1 Bleeding Events | 2 Bleeding Events | 4 Bleeding Events | |
| No Systemic Anticoagulation | 13 | 3 | 0 | 1 |
| Prismocitrate 18 | 16 | 1 | 0 | 0 |
"The point estimate is time point (number of hours of the extracorporeal circuit life of a filter) at which (100-percentile)% filters are still surviving (i.e. number surviving divided by number at risk), based on the Kaplan-Meier method. For example, for the 25th percentile: after 33.18 hours, 75% of filters are still surviving. Given the early termination, this study was not powered to show statistically significant changes in efficacy endpoints. The Prismaflex M150 Set extracorporeal circuit life of filters were intended to be assessed over a maximum of 120 hours (Treatment Period) by duration of time for which each Prismaflex M150 Set could be used continuously over a maximum 72 hour time-period in each patient. The end of the extracorporeal circuit life was defined by the occurrence of one or both of the following Prismaflex® System alarms/conditions if the alarms could not be mitigated: (1) Warning: Filter Clotted, and/or (2) Advisory transmembrane pressure (TMP) Too High." (NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | hours (Number) | ||
|---|---|---|---|
| 25 Percentile | 50 Percentile | 75 Percentile | |
| No Systemic Anticoagulation | 17.680 | 29.660 | NA |
| Prismocitrate 18 | 33.180 | NA | NA |
8 reviews available for citric acid, anhydrous and Hemorrhage
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Renal replacement therapy and anticoagulation.
Topics: Acute Kidney Injury; Anticoagulants; Citric Acid; Critical Illness; Hemorrhage; Heparin; Humans; Int | 2017 |
Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis.
Topics: Acid-Base Equilibrium; Adult; Anticoagulants; Citric Acid; Hemorrhage; Humans; Liver Failure; Renal | 2019 |
[Choice and management of anticoagulation during CRRT].
Topics: Acute Kidney Injury; Anticoagulants; Blood Coagulation; Buffers; Citric Acid; Hemorrhage; Heparin; H | 2019 |
Citrate anticoagulation for continuous renal replacement therapy in the critically ill.
Topics: Acid-Base Imbalance; Aged; Anticoagulants; Buffers; Citric Acid; Citric Acid Cycle; Clinical Protoco | 2010 |
Anticoagulation techniques in apheresis: from heparin to citrate and beyond.
Topics: Anticoagulants; Blood Component Removal; Calcium; Citric Acid; Hemorrhage; Heparin; Humans; Hypocalc | 2012 |
[Complications and adverse effects of plasmapheresis and their incidences].
Topics: Adolescent; Adult; Aged; Anticoagulants; Arrhythmias, Cardiac; Bacterial Infections; Citrates; Citri | 1984 |
16 trials available for citric acid, anhydrous and Hemorrhage
| Article | Year |
|---|---|
Regional Citrate Anticoagulation versus No-Anticoagulation for Continuous Venovenous Hemofiltration in Acute Severe Hypernatremia Patients with Increased Bleeding Risk: A Retrospective Cohort Study.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Citric Acid; Female; Hemodiafiltration; Hemorrhage; Huma | 2020 |
Modified regional citrate anticoagulation is optimal for hemodialysis in patients at high risk of bleeding: a prospective randomized study of three anticoagulation strategies.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Citric Acid; Dialysis Solutions; Female; Hemorrhage; | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap | 2020 |
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap | 2020 |
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap | 2020 |
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap | 2020 |
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap | 2020 |
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap | 2020 |
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap | 2020 |
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap | 2020 |
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap | 2020 |
A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CiTED study.
Topics: Aged; Anticoagulants; Blood Coagulation; Citric Acid; Cross-Over Studies; Dialysis Solutions; Female | 2017 |
An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis.
Topics: Aged; Anticoagulants; Blood Coagulation; Case-Control Studies; Citric Acid; Drug Liberation; Female; | 2018 |
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial.
Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th | 2019 |
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial.
Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th | 2019 |
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial.
Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th | 2019 |
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial.
Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th | 2019 |
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial.
Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th | 2019 |
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial.
Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th | 2019 |
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial.
Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th | 2019 |
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial.
Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th | 2019 |
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial.
Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th | 2019 |
Continuous venovenous hemodiafiltration with a low citrate dose regional anticoagulation protocol and a phosphate-containing solution: effects on acid-base status and phosphate supplementation needs.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Combined Modality Therapy; Female; Hemofiltr | 2013 |
[Evaluation of the application of regional citrate anticoagulation in sustained low efficiency hemodialysis].
Topics: Acute Kidney Injury; Anticoagulants; Blood Coagulation; Citrates; Citric Acid; Dialysis Solutions; F | 2014 |
[Role of local citrate anticoagulation in continuous blood purification to patients at high risk of bleeding in ICU].
Topics: Anticoagulants; Bicarbonates; Blood Coagulation; Blood Coagulation Tests; Calcium; Citrates; Citric | 2016 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
A significant proportion of patients treated with citrate containing dialysate need additional anticoagulation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Citric Acid; Cross-Ov | 2013 |
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per | 2004 |
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per | 2004 |
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per | 2004 |
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per | 2004 |
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per | 2004 |
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per | 2004 |
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per | 2004 |
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per | 2004 |
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per | 2004 |
Safety of citrate based hemofiltration in critically ill patients at high risk for bleeding: a comparison with nadroparin.
Topics: Anticoagulants; Citric Acid; Cohort Studies; Critical Illness; Erythrocyte Transfusion; Hemofiltrati | 2006 |
Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding.
Topics: Acrylic Resins; Adult; Aged; Anticoagulants; Citric Acid; Female; Hemorrhage; Heparin; Humans; Male; | 2007 |
Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding.
Topics: Acrylic Resins; Adult; Aged; Anticoagulants; Citric Acid; Female; Hemorrhage; Heparin; Humans; Male; | 2007 |
Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding.
Topics: Acrylic Resins; Adult; Aged; Anticoagulants; Citric Acid; Female; Hemorrhage; Heparin; Humans; Male; | 2007 |
Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding.
Topics: Acrylic Resins; Adult; Aged; Anticoagulants; Citric Acid; Female; Hemorrhage; Heparin; Humans; Male; | 2007 |
Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation.
Topics: Anticoagulants; Citrates; Citric Acid; Clinical Trials as Topic; Hemorrhage; Heparin; Humans; Prospe | 1987 |
40 other studies available for citric acid, anhydrous and Hemorrhage
| Article | Year |
|---|---|
Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Benzamidines; Child; Citrates; Citric Acid; Continuous Renal Re | 2022 |
[Attention should be paid to the application of regional citrate anticoagulation in blood purification].
Topics: Anticoagulants; Blood Coagulation; Citrates; Citric Acid; Hemorrhage; Heparin; Humans | 2023 |
Heparin anticoagulation versus regional citrate anticoagulation for membrane therapeutic plasma exchange in patients with increased bleeding risk.
Topics: Anticoagulants; Citrates; Citric Acid; Hemorrhage; Heparin; Humans; Plasma Exchange | 2023 |
Regional citrate anticoagulation versus no-anticoagulation for continuous venovenous hemofiltration in patients with liver failure and increased bleeding risk: A retrospective case-control study.
Topics: Adult; Aged; Anticoagulants; Case-Control Studies; Citric Acid; Cohort Studies; Continuous Renal Rep | 2020 |
Optimized calcium supplementation approach in post-dilution CVVHDF using regional citrate anticoagulation.
Topics: Anticoagulants; Blood Coagulation; Calcium; Citric Acid; Continuous Renal Replacement Therapy; Dialy | 2021 |
Regional citrate anticoagulation protocol suitable for intermittent hemodialysis and post-dilution hemodiafiltration.
Topics: Anticoagulants; Citric Acid; Hemodiafiltration; Hemorrhage; Humans; Renal Dialysis; Retrospective St | 2021 |
Clinical impact of regional citrate anticoagulation in continuous renal replacement therapy in critically ill patients.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Blood Coagulation; Citric Acid; Critical Illness; Female; | 2017 |
A novel DOPA-albumin based tissue adhesive for internal medical applications.
Topics: Animals; Biocompatible Materials; Bivalvia; Cattle; Citric Acid; Dopamine; Female; Fibrin Tissue Adh | 2017 |
Safety and efficacy of regional citrate anticoagulation in continuous blood purification treatment of patients with multiple organ dysfunction syndrome.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Blood Pressure; Citrates; Citric Acid; Female; Gluco | 2017 |
Rapid TEG efficiently guides hemostatic resuscitation in trauma patients.
Topics: Adult; Anticoagulants; Blood Transfusion; Citric Acid; Female; Hemorrhage; Hemostatic Techniques; Hu | 2018 |
A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Blood Coagulation; Calcium; Citric Acid; Continuou | 2019 |
Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk.
Topics: Acid-Base Equilibrium; Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Citric Acid; Fe | 2013 |
The combined use of pumpless extracorporeal lung assist and continuous arteriovenous hemofiltration with citrate anticoagulation in polytrauma patients.
Topics: Anticoagulants; Calcium Chelating Agents; Citric Acid; Extracorporeal Membrane Oxygenation; Hemofilt | 2015 |
Transition From Heparin to Citrate Anticoagulation for Continuous Renal Replacement Therapy: Safety, Efficiency, and Cost.
Topics: Aged; Anticoagulants; Australia; Calcium Chelating Agents; Citric Acid; Costs and Cost Analysis; Dru | 2016 |
Tissue distribution and acute toxicity of silver after single intravenous administration in mice: nano-specific and size-dependent effects.
Topics: Acetates; Animals; Brain; Chemical and Drug Induced Liver Injury; Citric Acid; Gallbladder Diseases; | 2016 |
Citrate Extended High Cut-Off Hemodiafiltration for Renal Recovery in Patients With Multiple Myeloma.
Topics: Aged; Aged, 80 and over; Anticoagulants; Citric Acid; Female; Hemodiafiltration; Hemorrhage; Humans; | 2016 |
Citrate anticoagulation in the ICU: the Leeds experience.
Topics: Acute Kidney Injury; Anticoagulants; Citric Acid; Critical Illness; England; Hemorrhage; Heparin; Hu | 2016 |
Pheochromocytoma Multisystem Crisis Triggered by Glucocorticoid Administration and Aggravated by Citrate Dialysis.
Topics: Adrenal Gland Neoplasms; Aged; Anti-Inflammatory Agents; Citric Acid; Dexamethasone; Echocardiograph | 2017 |
Regional citrate anticoagulation for continuous renal replacement therapy in children.
Topics: Acute Kidney Injury; Adolescent; Anticoagulants; Blood Coagulation; Child; Child, Preschool; Citric | 2017 |
A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges.
Topics: Adult; Aged; Algorithms; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Anticoagulants; | 2017 |
Comparison of the AN69ST Membrane versus Citrate-Enriched Dialysate on Clotting Events during Hemodialysis without Systemic Anticoagulation.
Topics: Adult; Blood Coagulation; Blood Pressure; Citric Acid; Dialysis Solutions; Female; Hemorrhage; Human | 2017 |
Regional citrate anticoagulation is safe in intermittent high-flux haemodialysis treatment of children and adolescents with an increased risk of bleeding.
Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Citric Acid; Female; Hemorrhage; Humans; Male; | 2010 |
Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Cardiac Surgical Pr | 2012 |
THE RELATIONSHIP of abnormal bleeding in surgical patients to administration of dextran, excesses of citrate and to fibrinolysis.
Topics: Citrates; Citric Acid; Dextrans; Fibrinolysin; Fibrinolysis; Hemorrhage; Hemorrhagic Disorders; Huma | 1956 |
THE RELATIONSHIP of abnormal bleeding in surgical patients to administration of dextran, excesses of citrate and to fibrinolysis.
Topics: Citrates; Citric Acid; Dextrans; Fibrinolysin; Fibrinolysis; Hemorrhage; Hemorrhagic Disorders; Huma | 1956 |
THE RELATIONSHIP of abnormal bleeding in surgical patients to administration of dextran, excesses of citrate and to fibrinolysis.
Topics: Citrates; Citric Acid; Dextrans; Fibrinolysin; Fibrinolysis; Hemorrhage; Hemorrhagic Disorders; Huma | 1956 |
THE RELATIONSHIP of abnormal bleeding in surgical patients to administration of dextran, excesses of citrate and to fibrinolysis.
Topics: Citrates; Citric Acid; Dextrans; Fibrinolysin; Fibrinolysis; Hemorrhage; Hemorrhagic Disorders; Huma | 1956 |
Bleeding after large transfusions of citrated blood; an experimental study.
Topics: Blood Transfusion; Citrates; Citric Acid; Hemorrhage; Humans; Platelet Transfusion | 1956 |
Bleeding after large transfusions of citrated blood; an experimental study.
Topics: Blood Transfusion; Citrates; Citric Acid; Hemorrhage; Humans; Platelet Transfusion | 1956 |
Bleeding after large transfusions of citrated blood; an experimental study.
Topics: Blood Transfusion; Citrates; Citric Acid; Hemorrhage; Humans; Platelet Transfusion | 1956 |
Bleeding after large transfusions of citrated blood; an experimental study.
Topics: Blood Transfusion; Citrates; Citric Acid; Hemorrhage; Humans; Platelet Transfusion | 1956 |
Does transfusion citrate cause hemorrhage?
Topics: Blood Preservation; Blood Transfusion; Citrates; Citric Acid; Heart Arrest; Hemorrhage; Humans; Teta | 1958 |
[Blood loss replacement with heparinized blood containing protamine-sulfate, citrate blood and crystalloid solutions].
Topics: Blood Transfusion; Citrates; Citric Acid; Crystalloid Solutions; Hemorrhage; Humans; Isotonic Soluti | 1961 |
[EFFECT OF STABILIZATION OF BLOOD WITH PREPARATIONS OF CITRIC ACID ON THE EFFECTIVENESS OF INTRA-ARTERIAL TRANSFUSION IN THE TREATMENT OF TERMINAL STATES CAUSED BY HEMORRHAGE].
Topics: Animals; Blood Pressure; Blood Pressure Determination; Blood Transfusion; Citrates; Citric Acid; Dea | 1963 |
[Efficacy of electrolyte solutions in blood losses. Comparative examinations on blood substitutes].
Topics: Blood Substitutes; Citric Acid; Electrolytes; Hemorrhage; Humans; Plasma Substitutes; Potassium | 1959 |
Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT).
Topics: Adolescent; Adult; Anticoagulants; Child; Child, Preschool; Citric Acid; Follow-Up Studies; Graft Oc | 2005 |
Citrate anticoagulation for single-needle hemodialysis: safety and efficacy.
Topics: Aged; Anticoagulants; Calcium Chloride; Catheters, Indwelling; Citric Acid; Female; Hemodialysis Sol | 2005 |
Prostacyclin versus citrate in continuous haemodiafiltration: an observational study in patients with high risk of bleeding.
Topics: Aged; Anticoagulants; Blood Platelets; Citric Acid; Epoprostenol; Female; Glucose; Hemodiafiltration | 2005 |
Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding.
Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Calcium; Citrates; Citric Acid; Female; | 1983 |
[Regional anticoagulation with sodium citrate: chronic utilization in the hemodialysis patient].
Topics: Aged; Aged, 80 and over; Anticoagulants; Bicarbonates; Calcium; Citrates; Citric Acid; Female; Hemat | 1993 |
Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.
Topics: Adult; Aged; Anticoagulants; Citric Acid; Female; Hemofiltration; Hemorrhage; Humans; Kidney Failure | 1999 |
Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.
Topics: Adult; Aged; Anticoagulants; Citric Acid; Female; Hemofiltration; Hemorrhage; Humans; Kidney Failure | 1999 |
Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.
Topics: Adult; Aged; Anticoagulants; Citric Acid; Female; Hemofiltration; Hemorrhage; Humans; Kidney Failure | 1999 |
Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.
Topics: Adult; Aged; Anticoagulants; Citric Acid; Female; Hemofiltration; Hemorrhage; Humans; Kidney Failure | 1999 |
Regional citrate anticoagulation for continuous arteriovenous hemodialysis. An update after 12 months.
Topics: Acute Kidney Injury; Citrates; Citric Acid; Evaluation Studies as Topic; Hemofiltration; Hemorrhage; | 1991 |
Citrate anticoagulation during in vivo simulation of slow hemofiltration.
Topics: Calcium; Citrates; Citric Acid; Female; Hemofiltration; Hemorrhage; Humans; Male; Renal Dialysis | 1990 |
[Regional anticoagulation with citrate in hemodialysis in patients with a high risk for hemorrhage].
Topics: Adult; Aged; Blood Coagulation; Calcium; Citrates; Citric Acid; Female; Hemorrhage; Humans; Male; Mi | 1988 |
Regional anticoagulation: hemodialysis with hypertonic trisodium citrate.
Topics: Bicarbonates; Blood Coagulation; Calcium; Citrates; Citric Acid; Hemorrhage; Heparin; Humans; Hypert | 1986 |
Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding.
Topics: Adult; Aged; Blood Coagulation Tests; Calcium; Chromogenic Compounds; Citrates; Citric Acid; Female; | 1985 |